Supernus Pharmaceuticals, Inc. (SUPN) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Supernus Pharmaceuticals, Inc. (SUPN) closed at USD 40.18 on 2026-10-14, a change of -24.4 % over the past year, with a market capitalization of USD 2.3B.

Supernus Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Supernus Pharmaceuticals, Inc. key figures

Previous close

USD 40.18 (2026-10-14)

1-year change

-24.4 %

Market cap

USD 2.3B

Enterprise value

USD 1.97B

P/E ratio (trailing)

-21.86

P/E ratio (forward)

9.19

EPS (trailing)

-1.81

EPS (forward)

4.31

PEG ratio

n/a

Price to book

2.23

Revenue growth

32.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.89

Employees

778

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Supernus Pharmaceuticals, Inc. and compare it with other stocks.